Does a moderate dose fish oil intervention improve outcomes in older adults recovering from hip fracture?

A Trial Assessing omega-3 fatty acids (N-3) as Treatment for Injury-induced Cachexia

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000241235

Acronym

ATLANTIC trial

Enrollment

150

Registered

2009-05-11

Start date

2010-08-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The anti-inflammatory properties of fish oil are well documented. Hip fracture is common and patients suffer significant unintentional weight and muscle loss leading to poor outcomes. An inflammatory response to the injury is a plausible mechanism for the lack of response observed in these patients when provided with best practice nutrition. This study aims to reduce the weight loss suffered by hip fracture patients by prescribing an intervention of individualised nutrition support and fish oil.

Interventions

12-week well integrated, coordinated, individualized nutrition therapy plan consistent with estimated nutritional requirements and nutritional rehabilitation goals combined with moderate dose liquid fish oil intervention (20ml/d; 3g eicosapentanoic acid (EPA) and 2g docosahexanoic acid (DHA)

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Healthy volunteers

Inclusion criteria

- Aged >65 years - PFF confirmed by radiology report - Undergone surgery for fixation of hip fracture - Reside within existing local service boundaries - Community dwelling - Preliminary evidence of cachexia (CRP =6mg/L) - At risk of significant weight loss (SNAQ score =14/20)

Exclusion criteria

- Severe cognitive impairment (MMSE <18/30) - PFF not fall-related, is pathological or is peri-prosthetic - Initiation of anti-inflammatory drugs or corticosteroids within the previous two weeks - Ingestion of =2g total omega-3 daily as per fish FFQ - Seafood allergy - Life expectancy <12 weeks - Inability to communicate effectively due to blindness, deafness or lack of a translator - Inability to provide informed consent - Diagnosed with one of the following haemorrhagic stroke risk factors (Unstable hypertension, Atrial fibrillation, Inherited disorders such as polycystic kidney disease, Ehlers-Danlos syndrome type IV, neurofibromatosis type I, Marfan syndrome, moyamoya disease) - Diagnosed with a bleeding disorders such as the following (von Willebrand disease or Haemophilia - Receiving treatment doses of any antithrombotic agent - Those on dual anti-platelet function drugs or any anti-platelet drugs with exception to low dose aspirin.

Outcome results